$52.5 million in Series C funding was raised by Carlsmed, a medtech startup that offers AI-enabled tailored surgery in Carlsbad, CA.
B Capital and U.S. Venture Partners lead the financing.
Under the direction of CEO Mike Cordonnier, Carlsmed has created the aprevo® individualized surgical platform, aimed at improving spine surgery care for individual patients.
The money will be used by the business to expedite the development of aprevo® for cervical fusions, which is scheduled to launch in 2025, and the commercialization of the tailored spine surgery platform aprevo® for lumbar fusion procedures.
“Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients,” Mike Cordonnier said in response to the announcement.
About Carlsmed
- Carlsmed is customizing the treatment of difficult adult spinal abnormalities by utilizing machine learning technologies and historical outcomes data. With the help of the company’s patented aprevo solution, surgical strategies and equipment are customized to each patient’s unique medical needs.
- Their goal is to revolutionize healthcare by providing spine surgeons with the necessary resources to ultimately achieve better outcomes at a reduced treatment cost, all the while assisting individuals in returning to active lifestyles.
- Carlsmed is a Connect | San Diego Venture Group 2020 Cool Company and a graduate of EvoNexus, the most successful nonprofit startup technology incubator in California.
